Diabetic cardiovascular disease: Getting to the heart of the matter

Journal of Cardiovascular Translational Research

Volumn 5, Issue 4, 2012, Pages 436-445

  Peterson, Linda R ^a   McKenzie, Clark R ^b   Schaffer, Jean E ^a  

^a WASHINGTON UNIVERSITY   (United States)

^b Mercy Clinic Heart and Vascular   (United States)

Author keywords

Coronary artery disease; Diabetes; Heart failure

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPLERENONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ARTICLE; CARDIOVASCULAR DISEASE; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CORONARY RISK; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHY; DISEASE COURSE; DRUG EFFICACY; DRUG ELUTING STENT; DYSLIPIDEMIA; EDEMA; HEART FAILURE; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOGENESIS; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROGNOSIS; SYSTOLIC DYSFUNCTION;

BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; CORONARY ARTERY DISEASE; DIABETES COMPLICATIONS; DIABETIC ANGIOPATHIES; HEART FAILURE; HUMANS; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS;

EID: 84866103916     PISSN: 19375387     EISSN: 19375395     Source Type: Journal    
DOI: 10.1007/s12265-012-9374-7     Document Type: Article

References (118)

1. Centers for Disease Control (2011). National Diabetes Fact Sheet. Available from: http://www.cdc.gov/diabetes/pubs/factsheet11.htm.
2. Kannel, W. B., & McGee, D. L. (1979). Diabetes and cardiovascular disease. The Framingham study. JAMA: The Journal of the American Medical Association, 241(19), 2035-2038.
3. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). (2001). JAMA, 285(19), 2486-2497.
4. Abbott, R. D., Donahue, R. P., Kannel, W. B., & Wilson, P. W. (1988). The impact of diabetes on survival following myocardial infarction in men vs women. The Framingham study. JAMA: The Journal of the American Medical Association, 260(23), 3456-3460.
5. Miettinen, H., Lehto, S., Salomaa, V., Mahonen, M., Niemela, M., Haffner, S. M., Pyorala, K., & Tuomilehto, J. (1998). Impact of diabetes on mortality after the first myocardial infarction. The Finmonica Myocardial Infarction Register Study Group. Diabetes Care, 21(1), 69-75.
6. Grundy, S. M., Pasternak, R., Greenland, P., Smith, S., Jr., & Fuster, V. (1999). Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the american heart association and the american college of cardiology. Circulation, 100(13), 1481-1492.
7. Malmberg, K., Yusuf, S., Gerstein, H. C., Brown, J., Zhao, F., Hunt, D., Piegas, L., Calvin, J., Keltai, M., & Budaj, A. (2000). Impact of diabetes on long-term prognosis in patients with unstable angina and non-q-wave myocardial infarction: results of the oasis (organization to assess strategies for ischemic syndromes) registry. Circulation, 102(9), 1014-1019.
8. Smith, J. W., Marcus, F. I., & Serokman, R. (1984). Prognosis of patients with diabetes mellitus after acute myocardial infarction. The American Journal of Cardiology, 54(7), 718-721.
9. Stone, P. H., Muller, J. E., Hartwell, T., York, B. J., Rutherford, J. D., Parker, C. B., Turi, Z. G., Strauss, H. W., Willerson, J. T., Robertson, T., et al. (1989). The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: contribution of both coronary disease and diastolic left ventricular dysfunction to the adverse prognosis. The Milis Study Group. Journal of the American College of Cardiology, 14 (1), 49-57.
10. Mak, K. H., Moliterno, D. J., Granger, C. B., Miller, D. P., White, H. D., Wilcox, R. G., Califf, R. M., & Topol, E. J. (1997). Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries. Journal of the American College of Cardiology, 30(1), 171-179.
11. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. (1996). Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Engl J Med, 335(4), 217-225.
12. Wingard, D. L., Barrett-Connor, E. L., Scheidt-Nave, C., & McPhillips, J. B. (1993). Prevalence of cardiovascular and renal complications in older adults with normal or impaired glucose tolerance or niddm. A population-based study. Diabetes Care, 16 (7), 1022-1025.
13. Goldberg, I. J. (2001). Clinical review 124: Diabetic dyslipidemia: causes and consequences. Journal of Clinical Endocrinology and Metabolism, 86(3), 965-971.
14. Ginsberg, H. N. (1996). Diabetic dyslipidemia: basic mechanisms underlying the common hypertriglyceridemia and low hdl cholesterol levels. Diabetes, 45(Suppl 3), S27-S30.
15. Haffner, S. M., Mykkanen, L., Festa, A., Burke, J. P., & Stern, M. P. (2000). Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state. Circulation, 101(9), 975-980.
16. Gordon, D. J., & Rifkind, B. M. (1989). High-density lipoprotein - the clinical implications of recent studies. The New England Journal of Medicine, 321(19), 1311-1316.
17. Austin, M. A., Breslow, J. L., Hennekens, C. H., Buring, J. E., Willett, W. C., & Krauss, R. M. (1988). Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA: The Journal of the American Medical Association, 260(13), 1917-1921.
18. Watts, G. F., & Karpe, F. (2011). Triglycerides and atherogenic dyslipidaemia: extending treatment beyond statins in the highrisk cardiovascular patient. Heart, 97(5), 350-356.
19. Jaleel, A., Henderson, G. C., Madden, B. J., Klaus, K. A., Morse, D. M., Gopala, S., & Nair, K. S. (2010). Identification of de novo synthesized and relatively older proteins: accelerated oxidative damage to de novo synthesized apolipoprotein a-1 in type 1 diabetes. Diabetes, 59(10), 2366-2374.
20. Boemi, M., Leviev, I., Sirolla, C., Pieri, C., Marra, M., & James, R. W. (2001). Serum paraoxonase is reduced in type 1 diabetic patients compared to non-diabetic, first degree relatives; influence on the ability of hdl to protect ldl from oxidation. Atherosclerosis, 155(1), 229-235.
21. Mastorikou, M., Mackness, M., & Mackness, B. (2006). Defective metabolism of oxidized phospholipid by HDL from people with type 2 diabetes. Diabetes, 55(11), 3099-3103.
22. Ceriello, A., Taboga, C., Tonutti, L., Quagliaro, L., Piconi, L., Bais, B., Da Ros, R., & Motz, E. (2002). Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: effects of short- and long-term simvastatin treatment. Circulation, 106(10), 1211-1218.
23. Morishita, R., Nakamura, S., Nakamura, Y., Aoki, M., Moriguchi, A., Kida, I., Yo, Y., Matsumoto, K., Nakamura, T., Higaki, J., & Ogihara, T. (1997). Potential role of an endothelium-specific growth factor, hepatocyte growth factor, on endothelial damage in diabetes. Diabetes, 46(1), 138-142.
24. Lehto, S., Niskanen, L., Suhonen, M., Ronnemaa, T., & Laakso, M. (1996). Medial artery calcification. A neglected harbinger of cardiovascular complications in non-insulin-dependent diabetes mellitus. Arteriosclerosis, Thrombosis, and Vascular Biology, 16 (8), 978-983.
25. Mazurek, T., Zhang, L., Zalewski, A., Mannion, J. D., Diehl, J. T., Arafat, H., Sarov-Blat, L., O'Brien, S., Keiper, E. A., Johnson, A. G., Martin, J., Goldstein, B. J., & Shi, Y. (2003). Human epicardial adipose tissue is a source of inflammatory mediators. Circulation, 108(20), 2460-2466.
26. Wang, C. P., Hsu, H. L., Hung, W. C., Yu, T. H., Chen, Y. H., Chiu, C. A., Lu, L. F., Chung, F. M., Shin, S. J., & Lee, Y. J. (2009). Increased epicardial adipose tissue (EAT) volume in type 2 diabetes mellitus and association with metabolic syndrome and severity of coronary atherosclerosis. Clinical Endocrinology, 70(6), 876-882.
27. Baker, A. R., Silva, N. F., Quinn, D. W., Harte, A. L., Pagano, D., Bonser, R. S., Kumar, S., & McTernan, P. G. (2006). Human epicardial adipose tissue expresses a pathogenic profile of adipocytokines in patients with cardiovascular disease. Cardiovascular Diabetology, 5, 1.
28. Marchant, B., Umachandran, V., Stevenson, R., Kopelman, P. G., & Timmis, A. D. (1993). Silent myocardial ischemia: role of subclinical neuropathy in patients with and without diabetes. Journal of the American College of Cardiology, 22(5), 1433-1437.
29. Kronmal, R. A., Barzilay, J. I., Tracy, R. P., Savage, P. J., Orchard, T. J., & Burke, G. L. (2004). The relationship of fasting serum radioimmune insulin levels to incident coronary heart disease in an insulin-treated diabetic cohort. Journal of Clinical Endocrinology and Metabolism, 89(6), 2852-2858.
30. Gerstein, H. C., Miller, M. E., Byington, R. P., Goff, D. C., Jr., Bigger, J. T., Buse, J. B., Cushman,W. C., Genuth, S., Ismail-Beigi, F., Grimm, R. H., Jr., Probstfield, J. L., Simons-Morton, D. G., & Friedewald, W. T. (2008). Effects of intensive glucose lowering in type 2 diabetes. The New England Journal of Medicine, 358(24), 2545-2559.
31. Patel, A.,MacMahon, S., Chalmers, J., Neal, B., Billot, L.,Woodward, M., Marre, M., Cooper, M., Glasziou, P., Grobbee, D., Hamet, P., Harrap, S., Heller, S., Liu, L.,Mancia, G., Mogensen, C. E., Pan, C., Poulter, N., Rodgers, A., Williams, B., Bompoint, S., de Galan, B. E., Joshi, R., & Travert, F. (2008). Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England Journal of Medicine, 358(24), 2560-2572.
32. Skyler, J. S., Bergenstal, R., Bonow, R. O., Buse, J., Deedwania, P., Gale, E. A., Howard, B. V., Kirkman, M. S., Kosiborod, M., Reaven, P., & Sherwin, R. S. (2009). Intensive glycemic control and the prevention of cardiovascular events: implications of the accord, advance, and va diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Circulation, 119(2), 351-357.
33. Gaede, P., Vedel, P., Larsen, N., Jensen, G. V., Parving, H. H., & Pedersen, O. (2003). Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. The New England Journal of Medicine, 348(5), 383-393.
34. Goldberg, R. B., Mellies, M. J., Sacks, F. M., Moye, L. A., Howard, B. V., Howard, W. J., Davis, B. R., Cole, T. G., Pfeffer, M. A., & Braunwald, E. (1998). Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the Cholesterol and Recurrent Events (CARE) trial. The Care Investigators. Circulation, 98(23), 2513-2519.
35. The Scandinavian Simvastatin Survival Study (4s) (1994). Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet, 344(8934), 1383-1389.
36. Pyorala, K., Pedersen, T. R., Kjekshus, J., Faergeman, O., Olsson, A. G., & Thorgeirsson, G. (1997). Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4s). Diabetes Care, 20(4), 614-620.
37. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. (1998). Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med, 339 (19), 1349-1357.
38. Heart Outcomes Prevention Evaluation Study Investigators. (2000). Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE Study and Micro-HOPE Substudy. Lancet 355(9200), 253-259.
39. Lindholm, L. H., Ibsen, H., Dahlof, B., Devereux, R. B., Beevers, G., de Faire, U., Fyhrquist, F., Julius, S., Kjeldsen, S. E.,Kristiansson, K., Lederballe-Pedersen, O., Nieminen, M. S., Omvik, P., Oparil, S., Wedel, H., Aurup, P., Edelman, J., & Snapinn, S. (2002). Cardiovascularmorbidity andmortality in patients with diabetes in the Losartan Intervention for Endpoint Reduction in Hypertension Study (LIFE): a randomised trial against atenolol. Lancet, 359(9311), 1004-1010.
40. Investigators, B. A. R. I. (2007). The final 10-year follow-up results from the BARI randomized trial. Journal of the American College of Cardiology, 49(15), 1600-1606.
41. Banning, A. P., Westaby, S., Morice, M. C., Kappetein, A. P., Mohr, F. W., Berti, S., Glauber, M., Kellett, M. A., Kramer, R. S., Leadley, K., Dawkins, K. D., & Serruys, P. W. (2010). Diabetic and nondiabetic patients with left main and/or 3-vessel coronary artery disease: comparison of outcomes with cardiac surgery and paclitaxel-eluting stents. Journal of the American College of Cardiology, 55(11), 1067-1075.
42. Chaitman, B. R., Hardison, R. M., Adler, D., Gebhart, S., Grogan, M., Ocampo, S., Sopko, G., Ramires, J. A., Schneider, D., & Frye, R. L. (2009). The bypass angioplasty revascularization investigation 2 diabetes randomized trial of different treatment strategies in type 2 diabetes mellitus with stable ischemic heart disease: impact of treatment strategy on cardiac mortality and myocardial infarction. Circulation, 120(25), 2529-2540.
43. Levy, D., Larson, M. G., Vasan, R. S., Kannel, W. B., & Ho, K. K. (1996). The progression from hypertension to congestive heart failure. JAMA: The Journal of the American Medical Association, 275(20), 1557-1562.
44. Owan, T. E., Hodge, D. O., Herges, R. M., Jacobsen, S. J., Roger, V. L., & Redfield, M. M. (2006). Trends in prevalence and outcome of heart failure with preserved ejection fraction. The New England Journal of Medicine, 355(3), 251-259.
45. Havranek, E. P., Masoudi, F. A., Westfall, K. A., Wolfe, P., Ordin, D. L., & Krumholz, H. M. (2002). Spectrum of heart failure in older patients: results from the national heart failure project. American Heart Journal, 143(3), 412-417.
46. Nichols, G. A., Hillier, T. A., Erbey, J. R., & Brown, J. B. (2001). Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors. Diabetes Care, 24(9), 1614-1619.
47. Kannel, W. B., Hjortland, M., & Castelli, W. P. (1974). Role of diabetes in congestive heart failure: the Framingham Study. The American Journal of Cardiology, 34, 29-34.
48. Hamby, R. I., Zoneraich, S., & Sherman, S. (1974). Diabetic cardiomyopathy. JAMA: The Journal of the American Medical Association, 229, 1749-1754.
49. Griffin, J. A., Osborn, B. W., & Smithline, H. A. (2005). The impact of diabetes on hospital admissions, length of stay and mortality in emergency department patients with acute decompensated heart failure without ischemia. Academic Emergency Medicine, 12, s97.
50. Das, S. R., Drazner, M. H., Yancy, C. W., Stevenson, L. W., Gersh, B. J., & Dries, D. L. (2004). Effects of diabetes mellitus and ischemic heart disease on the progression from asymptomatic left ventricular dysfunction to symptomatic heart failure: a retrospective analysis from the Studies of Left Ventricular Dysfunction (SOLVD) Prevention trial. American Heart Journal, 148(5), 883-888.
51. Fein, F. S., & Sonnenblick, E. H. (1985). Diabetic cardiomyopathy. Progress in Cardiovascular Diseases, 27(4), 255-270.
52. Fein, F. S. (1990). Diabetic cardiomyopathy. Diabetes Care, 13 (11), 1169-1179.
53. Fischer, M., Baessler, A., Hense, H. W., Hengstenberg, C., Muscholl, M., Holmer, S., Doring, A., Broeckel, U., Riegger, G., & Schunkert, H. (2003). Prevalence of left ventricular diastolic dysfunction in the community. Results from a doppler echocardiographicbased survey of a population sample. European Heart Journal, 24, 320-328.
54. Boyer, J. K., Thanigaraj, H., Schectman, K. B., & Perez, J. E. (2004). Prevalence of ventricular diastolic dysfunction in asymptomatic, normotensive patients with diabetes mellitus. The American Journal of Cardiology, 93, 870-875.
55. Di Bonito, P., Cuomo, S., Moio, N., Sibilio, G., Sabatini, D., Quattrin, S., & Capaldo, B. (1996). Diastolic dysfunction in patients with non-insulin-dependent diabetes mellitus of short duration. Diabetic Medicine, 13(4), 321-324.
56. Schannwell, C. M., Schneppenheim, M., Perings, S., Plehn, G., & Strauer, B. E. (2002). Left ventricular diastolic dysfunction as an early manifestation of diabetic cardiomyopathy. Cardiology, 98, 33-39.
57. Peterson, L. R., Waggoner, A. D., De las Fuentes, L., Schechtman, K. B., McGill, J. B., Gropler, R. J., & Davila-Roman, V. G. (2006). Alterations in left ventricular structure and function in type-1 diabetics: a focus on left atrial contribution to function. Journal of the American Society of Echocardiography, 19(6), 749-755.
58. Andersen, N. H., Poulsen, S. H., Eiskjaer, H., Poulsen, P. L., & Mogensen, C. E. (2003). Decreased left ventricular longitudinal contraction in normotensive and normoalbuminuric patients with type ii diabetes mellitus: a Doppler tissue tracking and strain rate echocardiography study. Clinical Science (London, England), 105(1), 59-66.
59. Ernande, L., Rietzschel, E. R., Bergerot, C., De Buyzere, M. L., Schnell, F., Groisne, L., Ovize, M., Croisille, P., Moulin, P., Gillebert, T. C., & Derumeaux, G. (2010). Impaired myocardial radial function in asymptomatic patients with type 2 diabetes mellitus: a speckletracking imaging study. Journal of the American Society of Echocardiography, 23(12), 1266-1272.
60. Ng, A. C., Delgado, V., Bertini, M., van der Meer, R.W., Rijzewijk, L. J., Shanks,M., Nucifora,G., Smit, J.W.,Diamant,M., Romijn, J. A., de Roos, A., Leung, D. Y., Lamb, H. J., & Bax, J. J. (2009). Findings from left ventricular strain and strain rate imaging in asymptomatic patients with type 2 diabetes mellitus. The American Journal of Cardiology, 104(10), 1398-1401.
61. Fang, Z. Y., Schull-Meade, R., Downey, M., Prins, J., & Marwick, T. H. (2005). Determinants of subclinical diabetic heart disease. Diabetologia, 48(2), 394-402.
62. Carugo, S., Giannattasio, C., Calchera, I., Paleari, F., Gorgoglione, M. G., Grappiolo, A., Gamba, P., Rovaris, G., Failla, M.,&Mancia, G. (2001). Progression of functional and structural cardiac alterations in young normotensive uncomplicated patients with type 1 diabetes mellitus. Journal of Hypertension, 19(9), 1675-1680.
63. Galderisi, M., Anderson, K. M., Wilson, P. W., & Levy, D. (1991). Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (the Framingham Heart Study). The American Journal of Cardiology, 68(1), 85-89.
64. Tenenbaum, A., Fisman, E. Z., Schwammenthal, E., Adler, Y., Benderly, M., Motro, M., & Shemesh, J. (2003). Increased prevalence of left ventricular hypertrophy in hypertensive women with type 2 diabetes mellitus. Cardiovascular Diabetology, 2, 4.
65. Lee, M., Gardin, J. M., Lynch, J. C., Smith, V. E., Tracy, R. P., Savage, P. J., Szklo, M., & Ward, B. J. (1997). Diabetes mellitus and echocardiographic left ventricular function in free-living elderly men and women: the Cardiovascular Health Study. American Heart Journal, 133, 36-43.
66. Devereux, R. B., Roman, M. J., Paranicas, M., O'Grady, M. J., Lee, E. T., Welty, T. K., Fabsitz, R. R., Robbins, D., Rhoades, E. R., & Howard, B. V. (2000). Impact of diabetes on cardiac structure and function: the Strong Heart Study. Circulation, 101 (19), 2271-2276.
67. Zarich, S.W., Arbuckle, B. E., Cohen, L. R., Roberts,M., & Nesto, R. W. (1988). Diastolic abnormalities in young asymptomatic diabetic patients assessed by pulsed doppler echocardiography. Journal of the American College of Cardiology, 12, 114-120.
68. Zarich, S. W., & Nesto, R. W. (1989). Diabetic cardiomyopathy. American Heart Journal, 118, 1000-1012.
69. Celentano, A., Vaccaro, O., Tammaro, P., Galderisi, M., Crivaro, M., Oliviero, M., Imperatore, G., Palmieri, V., Iovino, B., & Riccardi, G. (1995). Early abnormalities of cardiac function in non-insulin-dependent diabetes mellitus and impaired glucose tolerance. The American Journal of Cardiology, 76, 1173-1176.
70. Mustonen, J. N., Uusitupa, M. I., Laakso, M., Vanninen, E., Lansimies, E., Kuikka, J. T., & Pyorala, K. (1994). Left ventricular systolic function inmiddle-aged patients with diabetesmellitus. The American Journal of Cardiology, 73, 1202-1208.
71. From, A. M., Scott, C. G., & Chen, H. H. (2010). The development of heart failure in patients with diabetes mellitus and preclinical diastolic dysfunction: a population-based study. Journal of the American College of Cardiology, 55(4), 300-305.
72. Takeda, Y., Sakata, Y., Mano, T., Ohtani, T., Kamimura, D., Tamaki, S., Omori, Y., Tsukamoto, Y., Aizawa, Y., Komuro, I., & Yamamoto, K. (2011). Competing risks of heart failure with preserved ejection fraction in diabetic patients. European Journal of Heart Failure, 13(6), 664-669.
73. Parissis, J. T., Rafouli-Stergiou, P., Mebazaa, A., Ikonomidis, I., Bistola, V., Nikolaou, M., Meas, T., Delgado, J., Vilas-Boas, F., Paraskevaidis, I., Anastasiou-Nana,M., & Follath, F. (2012). Acute heart failure in patients with diabetes mellitus: clinical characteristics and predictors of in-hospital mortality. Int J Cardiol, 157, 108-113.
74. Masoudi, F. A., & Inzucchi, S. E. (2007). Diabetes mellitus and heart failure: epidemiology, mechanisms, and pharmacotherapy. The American Journal of Cardiology, 99(4A), 113B-132B.
75. Komajda, M., Carson, P. E., Hetzel, S., McKelvie, R., McMurray, J., Ptaszynska, A., Zile, M. R., Demets, D., & Massie, B. M. (2011). Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-Preserve). Circulation. Heart Failure, 4(1), 27-35.
76. Davis, B. R., Piller, L. B., Cutler, J. A., Furberg, C., Dunn, K., Franklin, S., Goff, D., Leenen, F., Mohiuddin, S., Papademetriou, V., Proschan, M., Ellsworth, A., Golden, J., Colon, P., & Crow, R. (2006). Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Circulation, 113(18), 2201-2210.
77. Domanski, M., Krause-Steinrauf, H., Deedwania, P., Follmann, D., Ghali, J. K., Gilbert, E., Haffner, S., Katz, R., Lindenfeld, J., Lowes, B. D., Martin, W., McGrew, F., & Bristow, M. R. (2003). The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial. Journal of the American College of Cardiology, 42(5), 914-922.
78. Giacco, F., & Brownlee, M. (2010). Oxidative stress and diabetic complications. Circulation Research, 107(9), 1058-1070.
79. Perez, J. E., McGill, J. B., Santiago, J. V., Schechtman, K. B., Waggoner, A. D., Miller, J. G., & Sobel, B. E. (1992). Abnormal myocardial acoustic properties in diabetic patients and their correlation with the severity of disease. Journal of the American College of Cardiology, 19, 1154-1162.
80. Barzilay, J. I., Kronmal, R. A., Gottdiener, J. S., Smith, N. L., Burke, G. L., Tracy, R., Savage, P. J., & Carlson, M. (2004). The association of fasting glucose levels with congestive heart failure in diabetic adults > or 065 years: the Cardiovascular Health Study. Journal of the American College of Cardiology, 43(12), 2236-2241.
81. Iribarren, C., Karter, A. J., Go, A. S., Ferrara, A., Liu, J. Y., Sidney, S., & Selby, J. V. (2001). Glycemic control and heart failure among adult patients with diabetes. Circulation, 103(22), 2668-2673.
82. Frustaci, A., Kajstura, J., Chimenti, C., Jakoniuk, I., Leri, A., Maseri, A., Nadal-Ginard, B., & Anversa, P. (2000). Myocardial cell death in human diabetes. Circulation Research, 87, 1123-1132.
83. Anderson, E. J., Kypson, A. P., Rodriguez, E., Anderson, C. A., Lehr, E. J., & Neufer, P. D. (2009). Substrate-specific derangements in mitochondrial metabolism and redox balance in the atrium of the type 2 diabetic human heart. Journal of the American College of Cardiology, 54(20), 1891-1898.
84. Young, M., McNulty, P., & Taegtmeyer, H. (2002). Adaptation and maladaptation of the heart in diabetes: part II: potential mechanisms. Circulation, 105, 1861-1870.
85. Horowitz, J., & Klein, S. (2000). Whole body and abdominal lipolytic sensitivity to epinephrine is suppressed in upper body obese women. American Journal of Physiology, 278, E1144- E1152.
86. Groop, L. C., Bonadonna, R. C., Del Prato, S., Ratheiser, K., Zyck, K., Ferrannini, E., & DeFronzo, R. A. (1989). Glucose and free fatty acid metabolism in non-insulin dependent diabetes mellitus: evidence for multiple sites of insulin resistance. The Journal of Clinical Investigation, 84, 205-213.
87. Miles, J. M., Wooldridge, D., Grellner, W. J., Windsor, S., Isley, W. L., Klein, S., & Harris, W. S. (2003). Nocturnal and postprandial free fatty acid kinetics in normal and type 2 diabetic subjects. Diabetes, 52, 675-681.
88. Peterson, L. R., Herrero, P., Schechtman, K. B., Racette, S. B., Waggoner, A. D., Kisrieva-Ware, Z., Dence, C., Klein, S., Marsala, J., Meyer, T., & Gropler, R. J. (2004). Effect of obesity and insulin resistance on myocardial substrate metabolism and efficiency in young women. Circulation, 109, 2191-2196.
89. Herrero, P., Peterson, L. R., McGill, J. B., Matthew, S., Lesniak, D., Dence, C., & Gropler, R. J. (2006). Increased myocardial fatty acid metabolism in patients with type 1 diabetes mellitus. Journal of the American College of Cardiology, 47(3), 598-604.
90. Diamant, M., Lamb, H., Groeneveld, Y., Endert, E., Smit, J., Bax, J., Romijn, J., de Roos, A., & Radder, J. (2003). Diastolic dysfunction is associated with altered myocardial metabolism in asymptomatic normotensive patients with well-controlled type 2 diabetes mellitus. Journal of the American College of Cardiology, 42, 328-335.
91. Scheuermann-Freestone, M., Madsen, P. L., Manners, D., Blamire, A. M., Buckingham, R. E., Styles, P., Radda, G. K., Neubauer, S.,& Clarke, K. (2003). Abnormal cardiac and skeletal muscle energy metabolism in patients with type 2 diabetes. Circulation, 107, 3040-3046.
92. Szczepaniak, L. S., Dibbins, R. L., Metzger, G. J., Sartoni- D'Ambrosia, G., Arbique, D., Vongpatanasin, W., Unger, R., & Victor, R. G. (2003). Myocardial triglycerides and systolic function in humans: in vivo evaluation by localized proton spectroscopy and cardiac imaging. Magnetic Resonance in Medicine, 49, 417-423.
93. Alavaikko, M., Elfving, R., Hirvonen, E. J., & Jarvi, J. (1973). Triglycerides, cholesterol, and phospholipids in normal heart papillary muscle and inpatients suffering from diabetes, cholelithiasis, hypertension, and coronary atheroma. Journal of Clinical Pathology, 26, 285-293.
94. Sharma, S., Adrogue, J. V., Golfman, L., Uray, I., Lemm, J., Youker, K., Noon, G. P., Frazier, O. H., & Taegtmeyer, H. (2004). Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart. The FASEB Journal, 18, 1692-1700.
95. Leinonen, J., Lehtimaki, T., Toyokuni, S., Okada, K., Tanaka, T., Hiai, H., Ochi, H., Laippala, P., Rantalaiho, V.,Wirta, O., Pasternack, A., & Alho, H. (1997). New biomarker evidence of oxidative DNA damage in patients with non-insulin-dependent diabetes mellitus. FEBS Letters, 417(1), 150-152.
96. Murakami, K., Kondo, T., Ohtsuka, Y., Fujiwara, Y., Shimada, M., & Kawakami, Y. (1989). Impairment of glutathione metabolism in erythrocytes from patients with diabetes mellitus. Metabolism, 38(8), 753-758.
97. Nourooz-Zadeh, J., Tajaddini-Sarmadi, J.,McCarthy, S., Betteridge, D. J., & Wolff, S. P. (1995). Elevated levels of authentic plasma hydroperoxides in NIDDM. Diabetes, 44(9), 1054-1058.
98. El-Mesallamy, H., Hamdy, N., Suwailem, S., & Mostafa, S. (2010). Oxidative stress and platelet activation: markers of myocardial infarction in type 2 diabetes mellitus. Angiology, 61(1), 14-18.
99. Iacobellis, G., Ribaudo, M. C., Zappaterreno, A., Vecci, E., Tiberti, C., Di Mario, U., & Leonetti, F. (2003). Relationship of insulin sensitivity and left ventricular mass in uncomplicated obesity. Obesity Research, 11(4), 518-524.
100. Rutter, M. K., Parise, H., Benjamin, E. J., Levy, D., Larson, M. G., Meigs, J. B., Nesto, R. W., Wilson, P. W., & Vasan, R. S. (2003). Impact of glucose intolerance and insulin resistance on cardiac structure and function: sex-related differences in the Framingham Heart Study. Circulation, 107(3), 448-454.
101. Abel, E. D. (2004). Insulin signaling in heart muscle: lessons from genetically engineered mouse models. Current Hypertension Reports, 6(6), 416-423.
102. Writing Team for the Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications Research Group, et al. (2002). Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA: The Journal of the American Medical Association, 287(19), 2563-2569.
103. UK Prospective Diabetes Study (UKPDS) Group, et al. (1998). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet, 352(9131), 837-853.
104. Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. (2008). 10-year follow-up of intensive glucose control in type 2 diabetes. The New England Journal of Medicine, 359 (15), 1577-1589.
105. Stratton, I. M., Adler, A. I., Neil, H. A., Matthews, D. R., Manley, S. E., Cull, C. A., Hadden, D., Turner, R. C., & Holman, R. R. (2000). Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ, 321(7258), 405-412.
106. Shekelle, P. G., Rich, M. W., Morton, S. C., Atkinson, C. S., Tu, W., Maglione, M., Rhodes, S., Barrett, M., Fonarow, G. C., Greenberg, B., Heidenreich, P. A., Knabel, T., Konstam, M. A., Steimle, A., & Warner Stevenson, L. (2003). Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. Journal of the American College of Cardiology, 41(9), 1529-1538.
107. Hunt, S. A., Baker, D. W., Chin, M. H., Cinquegrani, M. P., Feldman, A. M., Francis, G. S., Ganiats, T. G., Goldstein, S., Gregoratos, G., Jessup, M. L., Noble, R. J., Packer, M., Silver, M. A., Stevenson, L. W., Gibbons, R. J., Antman, E. M., Alpert, J. S., Faxon, D. P., Fuster, V., Jacobs, A. K., Hiratzka, L. F., Russell, R. O., & Smith, S. C., Jr. (2001). Acc/aha guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/ American Heart Association Task Force on practice guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). Journal of the American College of Cardiology, 38(7), 2101-2113.
108. Hou, F. F., Zhang, X., Zhang, G. H., Xie, D., Chen, P. Y., Zhang, W. R., Jiang, J. P., Liang, M.,Wang, G. B., Liu, Z. R., & Geng, R. W. (2006). Efficacy and safety of benazepril for advanced chronic renal insufficiency. The New England Journal of Medicine, 354 (2), 131-140.
109. Masoudi, F. A., & Havranek, E. P. (2001). Race and responsiveness to drugs for heart failure. The New England Journal of Medicine, 345(10), 767. author reply 767-8.
110. Lindholm, L. H., Ibsen, H., Borch-Johnsen, K., Olsen, M. H., Wachtell, K., Dahlof, B., Devereux, R. B., Beevers, G., de Faire, U., Fyhrquist, F., Julius, S., Kjeldsen, S. E., Kristianson, K., Lederballe-Pedersen, O., Nieminen, M. S., Omvik, P., Oparil, S., Wedel, H., Aurup, P., Edelman, J. M., & Snapinn, S. (2002). Risk of new-onset diabetes in the losartan intervention for endpoint reduction in hypertension study. Journal of Hypertension, 20(9), 1879-1886.
111. Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999). The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. The New England Journal of Medicine, 341(10), 709-717.
112. Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M. (2003). Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. The New England Journal of Medicine, 348(14), 1309-1321.
113. Packer, M., Coats, A. J., Fowler, M. B., Katus, H. A., Krum, H., Mohacsi, P., Rouleau, J. L., Tendera, M., Castaigne, A., Roecker, E. B., Schultz, M. K., & DeMets, D. L. (2001). Effect of carvedilol on survival in severe chronic heart failure. The New England Journal of Medicine, 344(22), 1651-1658.
114. Kirpichnikov, D., McFarlane, S. I., & Sowers, J. R. (2003). Heart failure in diabetic patients: utility of beta-blockade. Journal of Cardiac Failure, 9(4), 333-344.
115. Rhenman, M. J., Rhenman, B., Icenogle, T., Christensen, R., & Copeland, J. (1988). Diabetes and heart transplantation. The Journal of Heart Transplantation, 7(5), 356-358.
116. Marelli, D., Laks, H., Patel, B., Kermani, R., Marmureanu, A., Patel, J., & Kobashigawa, J. (2003). Heart transplantation in patients with diabetes mellitus in the current era. The Journal of Heart and Lung Transplantation, 22(10), 1091-1097.
117. Higgins, J., Pflugfelder, P. W., & Kostuk, W. J. (2009). Increased morbidity in diabetic cardiac transplant recipients. Canadian Journal of Cardiology, 25(4), e125-e129.
118. Hunt, S. A. (2005). ACC/AHA 2005 guideline update for the diagnosis andmanagement of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to update the 2001 guidelines for the evaluation and management of heart failure). Journal of the American College of Cardiology, 46(6), e1-e82.